(Q35117413)

6 August 2017

1 reference

title

Current therapies in Hodgkin's disease (English)

1 reference

6 August 2017

K. E. Kogel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721766

29 December 2023

J. W. Sweetenham

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721766

29 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12721766

29 December 2023

publication date

30 April 2003

1 reference

full work available at URL

6 August 2017

http://link.springer.com/content/pdf/10.1007/s00259-003-1156-7.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S00259-003-1156-7

http://link.springer.com/article/10.1007/s00259-003-1156-7/fulltext.html

29 December 2023

1 reference

https://api.crossref.org/works/10.1007/S00259-003-1156-7

http://link.springer.com/content/pdf/10.1007/s00259-003-1156-7

29 December 2023

1 reference

https://api.crossref.org/works/10.1007/S00259-003-1156-7

European Journal of Nuclear Medicine and Molecular Imaging

29 December 2023

published in

1 reference

6 August 2017

volume

30 Suppl 1

1 reference

6 August 2017

page(s)

S19-27

1 reference

Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-003-1156-7

Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-003-1156-7

British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-003-1156-7

Salvage Chemotherapy with ABVD in MOPP-Resistant Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-003-1156-7

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-003-1156-7

ChlVPP therapy for Hodgkin's disease: experience of 960 patients. The International ChlVPP Treatment Group

21 January 2018

1 reference

12 December 2020

Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study

1 reference

12 December 2020

ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial

1 reference

12 December 2020

Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease

1 reference

12 December 2020

Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study

1 reference

12 December 2020

Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease

1 reference

12 December 2020

Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease

1 reference

12 December 2020

Current strategies of antibody-based treatment in Hodgkin's disease

1 reference

12 December 2020

Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease.

1 reference

12 December 2020

Long-Term Complications of Treatment and Causes of Mortality After Hodgkin's Disease

1 reference

12 December 2020

High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation

1 reference

12 December 2020

Prognostic groups for management of localized Hodgkin's disease

1 reference

12 December 2020

Treatment of early and intermediate stage Hodgkin's lymphoma in the German Hodgkin's Lymphoma Study Group

1 reference

12 December 2020

The involved field is back: issues in delineating the radiation field in Hodgkin's disease

1 reference

12 December 2020

Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin

1 reference

12 December 2020

Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987.

1 reference

12 December 2020

Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial

1 reference

12 December 2020

Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin

1 reference

12 December 2020

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

12 December 2020

Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry

1 reference

12 December 2020

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report

1 reference

12 December 2020

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma

1 reference

12 December 2020

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

12 December 2020

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Gr

1 reference

12 December 2020

Lung function impairment in long-term survivors of Hodgkin's disease

1 reference

12 December 2020

Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation

1 reference

12 December 2020

Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease

1 reference

12 December 2020

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

12 December 2020

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group

1 reference

12 December 2020

The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy

1 reference

12 December 2020

Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP.

1 reference

12 December 2020

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

1 reference

12 December 2020

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

12 December 2020

CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease

1 reference

12 December 2020

Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease.

1 reference

12 December 2020

Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

12 December 2020

Long-term results of blood and marrow transplantation for Hodgkin's lymphoma

1 reference

12 December 2020

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

12 December 2020

Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment

1 reference

12 December 2020

Current clinical trials for advanced Hodgkin's lymphoma in North America: history, design and rationale

1 reference

12 December 2020

Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation

1 reference

12 December 2020

Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial

1 reference

12 December 2020

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.

1 reference

12 December 2020

Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease

1 reference

12 December 2020

Journal of Clinical Oncology

19

20

630

Horning

2002

1 reference

https://api.crossref.org/works/10.1007/S00259-003-1156-7

Proceedings of the American Association for Cancer Research

29 December 2023

20

8

13

DeVita

1967

1 reference

https://api.crossref.org/works/10.1007/S00259-003-1156-7

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

29 December 2023

series ordinal

39

1 reference

https://api.crossref.org/works/10.1007/S00259-003-1156-7

29 December 2023

Identifiers

1 reference

6 August 2017

1 reference